Ipratropium Bromide Accord Healthcare (Ipratropium Bromide)

Ipratropium bromide works by competitively blocking muscarinic (M3) receptors on airway smooth muscle. This inhibition prevents acetylcholine‑mediated calcium influx, which reduces muscle contraction and bronchoconstriction. The resulting bronchodilation improves airflow and eases symptoms of breathlessness in COPD and asthma.

The dose of ipratropium bromide is individualized by the prescribing healthcare professional based on the patient’s condition, severity, and response to therapy. The prescriber determines the appropriate number of inhalations per day and the specific device to be used.

Safety data for ipratropium bromide in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will assess each case and make an informed decision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Ipratropium bromide is an anticholinergic bronchodilator that provides longer‑lasting airway relaxation, especially useful in COPD. Albuterol is a short‑acting β2‑agonist that acts quickly to relieve acute bronchospasm. Clinicians often combine both agents to achieve complementary bronchodilation, with ipratropium offering a steadier effect and albuterol providing rapid relief.

The inhalation solution should be stored below 25 °C, in its original container, protected from moisture and direct light. Do not freeze the product. Keep the device out of reach of children and follow any additional handling instructions provided with the packaging.

The medication is delivered via a metered‑dose inhaler or nebulizer, as directed by the prescriber. Patients should inhale the prescribed number of puffs or nebulized doses, typically using a spacer or mouthpiece to ensure optimal deposition in the lungs. Proper inhalation technique should be reviewed with a healthcare professional.

The most serious risks include paradoxical bronchospasm, which can worsen breathing, and severe allergic reactions such as anaphylaxis. Patients should be monitored for sudden worsening of respiratory symptoms, rash, swelling, or difficulty breathing, and the medication should be discontinued immediately if these occur.

Ipratropium bromide is contraindicated in individuals with a known hypersensitivity to ipratropium, atropine, or any component of the formulation. Caution is also advised for patients with narrow‑angle glaucoma, urinary retention, or prostatic hypertrophy, as anticholinergic effects may exacerbate these conditions.